<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83370">
  <stage>Registered</stage>
  <submitdate>19/11/2008</submitdate>
  <approvaldate>3/12/2008</approvaldate>
  <actrnumber>ACTRN12608000602325</actrnumber>
  <trial_identification>
    <studytitle>A study to evaluate the safety of a single dose of increasing amounts of PF0713 given via a vein to healthy adult male volunteers</studytitle>
    <scientifictitle>A Phase 1, Open Label, Single-Center, Dose-Escalation, Cohort Study to Determine the Safety, Pharmacodynamics and Pharmacokinetics of a Single Intravenous (IV) Injection of PF0713 in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Anaesthesia</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single dose of PF0713 will be administered intravenously to each volunteer.  The initial dose will be 0.0156 mg/kg.  Doses will be increased by multiples of two.  The maximum dose will be determined based upon observed responses (e.g., anesthesia for more than 10 minutes).</interventions>
    <comparator>There is no comparator or control treatment.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety: Adverse events (e.g., slow or rapid heart rate, low or high blood pressure, or apnea will be assessed by repeated observation), clinical laboratory data, blood gases, vital signs, electrocardiogram (ECG), ventilation status, physical exam</outcome>
      <timepoint>Screening visit, treatment visit, end-of-study visit five days after treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tolerability: pain on injection, Quality of Recovery</outcome>
      <timepoint>Treatment visit</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacodynamics: Richmond Agitation Sedation Score, Bispectral Index</outcome>
      <timepoint>Treatment visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics</outcome>
      <timepoint>Blood will be sampled pre-dose, and 0.5, 1, 1.5, 2, 4, 8, 12, 15, 30, 60, 90 minutes, and 2, 4, 8, 24 hours post-dose.  Urine will be sampled 30 minutes pre-dose and from the following intervals post dose: 0-6 hours, 6-12 hours, 12-24 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Body mass index between 18 and 30 kg/m^2, blood pressure between 100-140/60-90 mmHg, heart rate between 50-99 beats per minute</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Problems with anesthesia, allergy or sensitivity to propofol or components of the formulation, regular tobacco use, alcohol or drug abuse in the past 2 years, enrollment in an investigational drug study within 30 days, American Society of Anesthesiologists Physical Status Classification greater than II.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>4/12/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>39</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>PharmacoFore, Inc.</primarysponsorname>
    <primarysponsoraddress>75 Shoreway Road, Suite D
San Carlos, CA 94070</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>PharmacoFore, Inc.</fundingname>
      <fundingaddress>75 Shoreway Road, Suite D
San Carlos, CA 94070</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to test the safety and the effect on the body of a drug called PF0713.  PF0713 is being developed for commencement and maintenance of anaesthesia and sedation.  The hypothesis is that PF0713 will produce anaesthetic effects and be well tolerated.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>27/10/2008</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lawrence Siegel</name>
      <address>PharmacoFore, Inc.
75 Shoreway Road, Suite D
San Carlos, CA  94070</address>
      <phone>1-650-331-4000, ext 4015</phone>
      <fax />
      <email>lsiegel@pharmacofore.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lawrence Siegel</name>
      <address>PharmacoFore, Inc.
75 Shoreway Road, Suite D
San Carlos, CA  94070</address>
      <phone>1-650-331-4000, ext 4015</phone>
      <fax />
      <email>lsiegel@pharmacofore.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lawrence Siegel</name>
      <address>PharmacoFore, Inc.
75 Shoreway Road, Suite D
San Carlos, CA  94070</address>
      <phone>1-650-331-4000, ext 4015</phone>
      <fax />
      <email>lsiegel@pharmacofore.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>